Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;18(5):29.
doi: 10.1007/s11912-016-0515-z.

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

Joyce F Liu  1 , Ursula A Matulonis  2
Affiliations
Review

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

Joyce F Liu et al. Curr Oncol Rep. 2016 May.

Abstract

Poly-ADP-ribose polymerase (PARP) inhibitors have been one of the most exciting developments in the treatment of ovarian cancer in recent years. Demonstration of anti-cancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014. Additional trials are underway or awaiting final analysis with olaparib, other PARPis, and PARPi combinations to further elucidate the activity of these drugs in various clinical settings. This review will focus on the current clinical experience and ongoing trials with PARPis in ovarian cancer.

Keywords: Niraparib; Olaparib; Ovarian cancer; PARP inhibitors; Rucaparib; Veliparib.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cancer Res. 2012 Nov 1;72 (21):5588-99 - PubMed
    1. Cancer Immunol Res. 2015 Nov;3(11):1257-68 - PubMed
    1. Gynecol Oncol. 2015 Jun;137(3):386-91 - PubMed
    1. Br J Cancer. 2012 Nov 6;107(10):1776-82 - PubMed
    1. Cancer Res. 2012 Nov 1;72(21):5454-62 - PubMed

MeSH terms